blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3572413

EP3572413 - 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.09.2022
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  01.10.2021
FormerGrant of patent is intended
Status updated on  22.07.2021
FormerRequest for examination was made
Status updated on  25.10.2019
FormerThe international publication has been made
Status updated on  28.07.2018
Most recent event   Tooltip27.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 30.10.2024 [2024/44]
Applicant(s)For all designated states
Wuxi Biocity Biopharmaceutics Co., Ltd.
Room 315, Meiliang Road No.88
Mashan, Binhu District
Wuxi, Jiangsu 214000 / CN
[2022/30]
Former [2019/48]For all designated states
Shijiazhuang Sagacity New Drug Development Co., Ltd.
Floor 3, Innovation Building
Changjiang Road No. 315
New and Hi-Tech District
Shijiazhuang, Hebei 050035 / CN
Inventor(s)01 / QIAN, Wenyuan
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
02 / YANG, Chundao
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
03 / LI, Zhengwei
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
04 / LI, Jie
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
05 / LI, Jian
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
06 / CHEN, Shuhui
288 Futezhong Road
Pudong New Area
Shanghai 200131 / CN
 [2019/48]
Representative(s)Haseltine Lake Kempner LLP
One Portwall Square
Portwall Lane
Bristol BS1 6BH / GB
[N/P]
Former [2019/48]Haseltine Lake Kempner LLP
Redcliff Quay
120 Redcliff Street
Bristol BS1 6HU / GB
Application number, filing date18741681.319.01.2018
[2019/48]
WO2018CN73360
Priority number, dateCN2017105885623.01.2017         Original published format: CN201710058856
CN20171137676919.12.2017         Original published format: CN201711376769
[2019/48]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018133829
Date:26.07.2018
Language:ZH
[2018/30]
Type: A1 Application with search report 
No.:EP3572413
Date:27.11.2019
Language:EN
[2019/48]
Type: B1 Patent specification 
No.:EP3572413
Date:03.11.2021
Language:EN
[2021/44]
Search report(s)International search report - published on:CN26.07.2018
(Supplementary) European search report - dispatched on:EP17.07.2020
ClassificationIPC:C07D471/04, A61K31/519, A61P35/00, C07D519/00
[2020/34]
CPC:
C07D519/00 (EP,US); A61K31/519 (EP); A61P35/00 (EP)
Former IPC [2019/48]C07D471/04, A61K31/519, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/48]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ON DERIVATE ALS WEE-1-HEMMER[2019/48]
English:1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR[2019/48]
French:DÉRIVÉ DE 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE UTILISÉ EN TANT QU'INHIBITEUR DE WEE1[2019/48]
Entry into regional phase22.08.2019Translation filed 
22.08.2019National basic fee paid 
22.08.2019Search fee paid 
22.08.2019Designation fee(s) paid 
22.08.2019Examination fee paid 
Examination procedure22.08.2019Examination requested  [2019/48]
02.02.2021Amendment by applicant (claims and/or description)
23.07.2021Communication of intention to grant the patent
28.09.2021Fee for grant paid
28.09.2021Fee for publishing/printing paid
28.09.2021Receipt of the translation of the claim(s)
Opposition(s)04.08.2022No opposition filed within time limit [2022/41]
Fees paidRenewal fee
28.01.2020Renewal fee patent year 03
26.01.2021Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.01.2018
AL03.11.2021
AT03.11.2021
CY03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
MK03.11.2021
MT03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
IE19.01.2022
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
[2024/44]
Former [2024/24]HU19.01.2018
AL03.11.2021
AT03.11.2021
CY03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
MK03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
IE19.01.2022
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2024/23]AL03.11.2021
AT03.11.2021
CY03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
MK03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
IE19.01.2022
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2024/20]AL03.11.2021
AT03.11.2021
CY03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
IE19.01.2022
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2023/09]AL03.11.2021
AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
IE19.01.2022
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2023/03]AL03.11.2021
AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
LU19.01.2022
BE31.01.2022
CH31.01.2022
LI31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2023/01]AL03.11.2021
AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SI03.11.2021
SK03.11.2021
SM03.11.2021
LU19.01.2022
BE31.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/49]AL03.11.2021
AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SK03.11.2021
SM03.11.2021
LU19.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/46]AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SK03.11.2021
SM03.11.2021
LU19.01.2022
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/39]AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
MC03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SK03.11.2021
SM03.11.2021
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/35]AT03.11.2021
CZ03.11.2021
DK03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SK03.11.2021
SM03.11.2021
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/34]AT03.11.2021
EE03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
NL03.11.2021
PL03.11.2021
RO03.11.2021
RS03.11.2021
SE03.11.2021
SM03.11.2021
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/33]AT03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
NL03.11.2021
PL03.11.2021
RS03.11.2021
SE03.11.2021
SM03.11.2021
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/25]AT03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
NL03.11.2021
PL03.11.2021
RS03.11.2021
SE03.11.2021
BG03.02.2022
NO03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/24]AT03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
NL03.11.2021
PL03.11.2021
RS03.11.2021
SE03.11.2021
BG03.02.2022
GR04.02.2022
IS03.03.2022
PT03.03.2022
Former [2022/23]AT03.11.2021
FI03.11.2021
HR03.11.2021
LT03.11.2021
LV03.11.2021
PL03.11.2021
RS03.11.2021
BG03.02.2022
PT03.03.2022
Former [2022/22]AT03.11.2021
FI03.11.2021
LT03.11.2021
RS03.11.2021
BG03.02.2022
Former [2022/21]AT03.11.2021
RS03.11.2021
BG03.02.2022
Former [2022/19]BG03.02.2022
Documents cited:Search[AD]WO2007126122  (BANYU PHARMA CO LTD [JP], et al) [AD] 1-15 * compounds of the examples, especially Example 9; page 1, paragraph 1; claims 1,6-8 *;
 [AD]EP2213673  (BANYU PHARMA CO LTD [JP]) [AD] 1-15 * page 1, paragraph 1; example 32; claims 1,10-12 *;
 [A]WO2016000581  (MEDSHINE DISCOVERY INC [CN], et al) [A] 1-15 * examples 15-25; claims 1,11,14 *
International search[A]CN101432284  (BANYU PHARMA CO LTD [JP]) [A] 1-22 * , description, pages 2-4, and embodiment 53 *;
 [A]CN105829315  (ALMAC DISCOVERY LTD) [A] 1-22 * , description, pages 3 and 4 *;
 [A]CN105209463  (ALMAC DISCOVERY LTD) [A] 1-22 * , description, pages 2-4 *;
 [A]CN104130265  (SU ZHOU JING HONG BIOTECH CO LTD) [A] 1-22 * , description, pages 2 and 3 *;
 [A]CN103703005  (ABBOTT LAB) [A] 1-22 * , description, pages 1-9 *;
 [A]EP2213673  (BANYU PHARMA CO LTD [JP]) [A] 1-22 * , pages 4, 5 and 71 *
by applicantUS2007254892
 WO2007126122
 EP2213673
 WO2008133866
 WO2011034743
 US2012220572
 WO2013126656
 WO2013012681
 WO2013059485
 WO2013013031
 WO2014167347
 WO2015019037
 WO2015092431
    - BERGE et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.